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Endoglin (also known as CD105 or TGF-β type III receptor) 
is a co-receptor involved in TGF-β signaling. In athero-
sclerosis, TGF-β signaling is crucial in regulating disease 
progression owing to its anti-inflammatory effects as well as 
its inhibitory effects on smooth muscle cell proliferation and 
migration. Endoglin is a regulator of TGF-β signaling, but its 
role in atherosclerosis has yet to be defined. This review fo-
cuses on the roles of the various forms of endoglin in 
atherosclerosis. The expression of the two isoforms of endo-
glin (long-form and short-form) is increased in athero-
sclerotic lesions, and the expression of the soluble forms of 
endoglin is upregulated in sera of patients with hyper-
cholesterolemia and atherosclerosis. Interestingly, long-form 
endoglin shows an atheroprotective effect via the induction 
of eNOS expression, while short-form and soluble endoglin 
enhance atherogenesis by inhibiting eNOS expression and 
TGF-β signaling. This review summarizes evidence suggest-
ing that the different forms of endoglin have distinct roles in 
atherosclerosis.
[Immune Network 2014;14(5):237-240]




TGF-β is a multi-functional cytokine and its signaling path-
way contributes to a wide range of immunological and bio-
logical effects on various cell types and several diseases. TGF-β 
has regulatory functions in cell proliferation, differentiation, 
migration, and survival that affect multiple biological proc-
esses such as cell development, carcinogenesis, fibrosis, and 
wound healing, as well as immune responses (1). There is 
some controversy in the literature as to the precise functions 
of TGF-β; for example, in atherosclerosis, it is not clear 
whether TGF-β is pro-atherogenic or anti-atherogenic. The 
inhibition of TGF-β1 activity induces pro-atherogenic 
changes in the vessel wall of atherosclerotic animal models 
(2). Furthermore, the neutralization of TGF-β1 leads to an 
inflammatory response of the vessel wall and provokes pla-
que instability (3). After the engagement of TGF-β type I 
& II receptors, the Smad-dependent pathways are activated. 
The biological effects that result depend on the types of Smad 
complex involved in this signaling response (4). This process 
is modulated by other accessory receptors such as TGF-β 
type III receptor (5). The major type III receptor expressed 
in atherosclerotic lesions is endoglin. Although the expression 
of endoglin is increased in atherosclerotic lesions, the func-
tional roles of endoglin in atherosclerosis have not been fully 
clarified. This review aims to suggest a hypothetical role for 
endoglin in atherosclerosis on the basis of previous reports. 
STRUCTURE AND EXPRESSION
Endoglin (CD105) is a homodimer composed of two identical 
95 kDa disulfide-linked subunits, and it is known as a hypo-
xia-inducible transmembrane glycoprotein (6). It consists of 
three domains: a large extracellular domain, a transmem-
brane domain, and a short intracellular domain. The ex-
tracellular domain contains an Arg-Gly-Asp (RGD) tri-peptide, 
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four N-linked glycosylation sites, and one O-linked glyco-
sylation site (7). The intracellular domain includes several ser-
ine and threonine residues, some of which are phosphor-
ylation sites (8). The human endoglin gene, which is located 
on chromosome 9, is composed of 15 exons. The ex-
tracellular domain of endoglin is coded by exons 1∼13 (9). 
Endoglin homologues have been identified in mice and pigs; 
the amino acid sequences of these homologues each have 
more than 70% identity with human endoglin and more than 
69% homology with β-glycan, another type III TGF-β re-
ceptor (TGF-βR) (10). Two isoforms of endoglin were re-
ported, long-form endoglin and short-form endoglin, which 
differ in the length of their intracellular domains and the de-
gree of phosphorylation. Long-form endoglin has 47 amino 
acids in its cytoplasmic tail, has a high degree of phosphor-
ylation and is expressed predominantly in endothelial cells, 
whereas short-form endoglin has only 14 amino acids in its 
intracellular domain and has a low level of phosphorylation 
(6,11). A soluble form of endoglin has also been identified 
in the sera of both cancer patients and healthy persons. 
Soluble forms are generated by the cleavage of the ex-
tracellular domain of endoglin by membrane-type metal-
loprotease-14 (MMP-14), which may serve as a naturally oc-
curring antagonist for TGF-β signaling (12). MMP-14 cleaves 
endoglin at position 586 to release a soluble fragment repre-
senting almost the entire endoglin extracellular domain (13). 
MMP-14 is highly expressed in malignant epithelial cells and 
endothelial cells. 
  Endoglin is expressed by various cells found in the blood 
vessel wall, including endothelial cells, monocytes/macro-
phages, fibroblasts and vascular smooth muscle cells (14). 
Endoglin is upregulated during wound healing and tumor 
vascularization and in inflammatory tissues and developing 
embryos. Endoglin expression in blood vessels is increased 
during hypoxia or following vascular injury. In hypoxic con-
ditions, endoglin transcription is induced by the formation of 
a multiprotein complex with Smad3/Smad4, stimulating pro-
tein 1 (Sp1), and hypoxia-inducible factor-1 (HIF-1) (15). 
Smad-dependent TGF-β signaling also enhances endoglin 
expression whereas TNF-β was reported to inhibit the ex-
pression of endoglin by endothelial cells (16,17). In contrast 
to these results, expression of the soluble form of endoglin was 
increased following treatment with TNF-β and hydrogen per-
oxide, which are known as pro-atherogenic mediators (18). 
FUNCTION
Endoglin was originally identified as a non-signaling co-re-
ceptor for TGF-β since it does not contain intrinsic kinase 
activity. The main function of endoglin is thought to be the 
regulation of TGF-β signaling via interactions with several 
proteins within the TGF-β signaling pathway. Endoglin binds 
to both of the TGF-β1 and TGF-β3 isoforms, following 
which the cytosolic domain of endoglin can be targeted by 
serine and threonine kinases, leading to the formation of a 
functional receptor complex (19). Indeed, endoglin is not a 
true receptor for TGF-β, but it strongly modulates the phos-
phorylation levels of TGF-βRII, activin receptor-like kinase 
(ALK)-1, and ALK-5 (20). The presence of endoglin can also 
modulate the downstream signaling by TGF-βRI/TGF-βRII 
complexes. Recent studies have demonstrated that endoglin 
functions in an interplay between two signaling pathways in-
volving ALK-1 and ALK-5, respectively, that have differential 
effects on target cells. Endoglin/ALK-1/Smad1/5 signaling 
stimulates the migration, proliferation, and tube formation of 
endothelial cells, resulting in angiogenesis (21). In contrast, 
the endoglin/ALK-5/Smad2 pathway inhibits the activity of 
endothelial cells and angiogenesis by inhibiting the pro-
liferation, tube formation, and migration of endothelial cells 
(22). In addition, endoglin has inhibitory effects on Smad3- 
dependent TGF-β signaling, resulting in effects on endothe-
lial cells opposite to those that result from Smad2-dependent 
signaling (23). Mutations in endoglin have been reported in 
hereditary hemorrhagic telangiectasia, a disease characterized 
by malformations of vascular structure (24). The long-form 
and short-form endoglin isoforms are both able to bind to 
their ligands and interact with ALK-1 and ALK-5; however, 
the two membrane-bound endoglin isoforms differ in their af-
finity for each receptor, level of phosphorylation, and ca-
pacity to regulate TGF-β-dependent responses (25). Long- 
form endoglin has pro-angiogenic effects through induction 
of endogenous nitric oxide synthase (eNOS) expression, 
whereas short-form endoglin has anti-angiogenic effects. 
Thus, short-form endoglin contributes to the cardiovascular 
pathology associated with senescence. In addition, soluble 
endoglin, which inhibits TGF-β signaling, is thought to be 
cleaved from the cell membrane and enter the systemic circu-
lation, and may represent a useful candidate marker of endo-
thelial injury, activation, inflammation, and senescence (12).
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ENDOGLIN AND ATHEROSCLEROSIS
Atherosclerosis is a chronic inflammatory disease of the 
arteries. Endothelial dysfunction plays an important role in 
the development of atherosclerosis by inducing infiltration of 
inflammatory cells and a prothrombogenic state. In addition, 
the migration and proliferation of smooth muscle cells, which 
are processes that affect the plaque stability, are crucial in 
the progression of advanced atherosclerotic lesions. TGF-β 
signaling results in inhibition of the proliferation and migra-
tion of smooth muscle cells, as well as endothelial cell re-
generation (26). It was also reported that inhibition of TGF-β 
signaling reduced collagen content and plaque stability in a 
mouse model of atherosclerosis (3). In this model, TGF-β 
showed a protective effect against atherogenesis. Therefore, 
as an accessory receptor for TGF-β, endoglin expressed by 
endothelial cells and smooth muscle cells may play an im-
portant role in modifying the development of atherosclerosis 
via the regulation of TGF-β-induced atheroprotective effects. 
Although the expression of endoglin was very low in non- 
atherosclerotic aortas, the expression of endoglin by macro-
phages, smooth muscle cells and endothelial cells was in-
creased in early atherosclerotic lesions (14). In advanced 
atherosclerotic plaques, smooth muscle cells expressed high 
levels of endoglin, a parameter that was independent of 
smooth muscle cell morphology and leukocyte infiltration. 
Moreover, endoglin modulates the expression of genes that 
are known to be related to pro-angiogenic effects (VEGF, an-
giopoietin-1, and angiopoeitin-2) or anti-angiogenic effects 
(Notch signaling, Notch-3, and DLL4), respectively (27,28). 
Several studies have also reported that the concentration of 
soluble endoglin increased in the blood of patients with hy-
percholesterolemia and atherosclerosis (29). Increased solu-
ble endoglin levels could be related to endothelial damage 
or dysfunction; furthermore, soluble endoglin is an indicator 
of cardiovascular damage in hypertension and diabetes-asso-
ciated vascular pathologies (30). The circulating concentration 
of soluble endoglin was reported to increase at early stages 
of atherosclerosis due to damage of endothelial cells and then 
decrease in later stages of atherosclerosis, which suggests a 
potential role of soluble endoglin in acute heart failure (31). 
As a decoy receptor, soluble endoglin may inhibit the an-
ti-atherogenic effects induced by TGF-β. 
CONCLUSION
The expression levels of endoglin and soluble endoglin were 
higher in atherogenic lesions than in healthy arteries. Two 
isoforms of endoglin differentially transduce TGF-β signaling 
by activation of different Smad components, and thereby 
modulate the biological effects of TGF-β signaling. 
Long-form endoglin shows atheroprotective effect by in-
duction of eNOS expression, while short-form endoglin and 
soluble endoglin forms enhance atherogenesis via down-
regulation of eNOS expression and inhibition of TGF-β 
signaling.
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